Greenwich LifeSciences, Inc.
GLSINasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$19.4M | −$16.0M | −$9.3M | −$8.0M | −$4.6M | −$1.9M |
| Net income | −$2.7M | −$15.8M | −$8.9M | −$7.8M | −$4.6M | −$1.9M |
| Total assets | $6.2M | $4.1M | $7.0M | $13.5M | $27.2M | $28.7M |
| Total liabilities | $2.6M | $1.6M | $294,406 | $262,905 | $385,172 | $1.0M |
| Equity | $353,217 | $2.5M | $6.7M | $13.2M | $26.8M | $27.6M |
| EPS (diluted) | $-0.21 | $-1.21 | $-0.69 | $-0.61 | $-0.35 | — |
| Shares out. | 13.3M | 12.9M | 12.8M | 13.0M | 12.8M | 12.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −777.1%
- Return on assets
- −44.4%
- Return on capital (ROCE)
- −5505.9%
- Liabilities / assets
- 41.3%
- Debt / equity
- 7.22×
- Book value / share
- $0.03
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -66.61distress
- Accruals / assets
- −14.7%clean
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 31, 2026
- NT 10-Qmissed a reporting deadline ↗May 15, 2025
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2025
- NT 10-Qmissed a reporting deadline ↗May 15, 2024
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2024
- NT 10-Qmissed a reporting deadline ↗Aug 14, 2023
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.5M | 11.0 | -0.2% |
| Apr 30, 2026 | 1.5M | 11.0 | +1.4% |
| Apr 15, 2026 | 1.5M | 13.1 | +1.3% |
| Mar 31, 2026 | 1.5M | 7.5 | +5.9% |
| Mar 13, 2026 | 1.4M | 9.0 | +6.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Shareholder voteDec 18, 2025
- Changed auditorJul 24, 2025
- Shareholder voteDec 19, 2024
- Entered a material agreement · Unregistered equity saleJun 17, 2024
- Changed auditorFeb 20, 2024
- Other material eventFeb 14, 2024
- Shareholder voteDec 15, 2023
- Other material eventApr 13, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.